Macular HolesFTMH-10NCT07606404
Full-Thickness Macular Hole Surgery: A Comparison of Ten Techniques
A study testing Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery, Autologous Platelet-Rich Plasma (PRP) and Human Amniotic Membrane (hAM) Graft in people with Macular Holes, run by Kazakh Eye Research Institute at 1 site in Kazakhstan.
Trial summary
This study compares ten modern vitreoretinal surgical techniques for full-thickness macular hole repair. Participants will be randomly assigned to one of the surgical approaches during pars plana vitrectomy, using stratified randomization based on macular hole size to ensure balanced groups. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Macular Holes
- What is being tested?
- Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery, Autologous Platelet-Rich Plasma (PRP) and Human Amniotic Membrane (hAM) Graft
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteKazakhstan
- Study dates
- 25 May 2026to 27 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged ≥18 years.
- Full-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV).
- Symptom duration ≤12 months.
- Clear ocular media sufficient for high-quality OCT imaging.
- No prior pars plana vitrectomy in the study eye.
- No severe foveal atrophy on OCT.
- Able and willing to comply with postoperative positioning and follow-up visits.
- Written informed consent provided.
Who cannot join
- Etiology-Related / Secondary Macular Holes:
- Traumatic macular hole.
- High myopia with posterior staphyloma (axial length >28 mm and/or spherical equivalent ≤-8.0 D).
- Diabetic tractional retinal detachment (TRD) or significant tractional maculopathy.
- Retinal vascular occlusion-related macular hole.
- Uveitis-related macular hole.
Show all 14Show fewer
- Advanced age-related macular degeneration (AMD) with foveal atrophy.
- Prior Interventions:
- Any prior pars plana vitrectomy in the study eye.
- Ocular Conditions That May Affect Outcomes or Safety:
- Active or recent ocular infection or inflammation (e.g., uveitis, endophthalmitis, keratitis).
- Uncontrolled glaucoma (intraocular pressure >28 mmHg despite treatment).
- Media opacity precluding adequate OCT (e.g., dense cataract or corneal opacity).
- Geographic atrophy involving the fovea.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Kazakhstan1 site, 1 recruiting
- Recruiting
Kazakh Eye Research Institute
Almaty, Almaty, 050042
Sanzhar Sambet, MD, +77758719834, sanzhrs@gmail.com
About this study
Official title: Vitreoretinal Surgery for Full-Thickness Macular Hole: A Comparative Study of Ten Techniques
This study compares ten modern vitreoretinal surgical techniques for full-thickness macular hole repair. Participants will be randomly assigned to one of the surgical approaches during pars plana vitrectomy, using stratified randomization based on macular hole size to ensure balanced groups. The main goal is to determine which technique provides the highest anatomical closure rate on optical coherence tomography (OCT) and the best visual outcomes. Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery to assess OCT findings, visual acuity, safety outcomes, and the need for reoperation.
Read the detailed description
Full-thickness macular hole is a vision-threatening condition that is commonly treated with pars plana vitrectomy (PPV) and internal limiting membrane (ILM) peeling. While standard approaches achieve high closure rates in many cases, outcomes may vary depending on macular hole size and OCT morphology, and advanced surgical strategies (e.g., different ILM flap configurations, adjunctive biologic augmentation, hydrodissection, or grafting techniques) are increasingly used in clinical practice.
This single-center, randomized, parallel-group interventional study will compare ten PPV-based surgical techniques for full-thickness macular hole repair. Eligible participants will include adults with full-thickness macular hole across a broad range of minimum linear diameter (MLD), including MLD <250 µm. After eligibility confirmation and informed consent, participants will be randomized to one of the ten procedure groups. Randomization will be stratified by macular hole size into five predefined MLD strata to ensure balanced distribution of hole sizes across all intervention groups. Postoperative care and follow-up procedures will be standardized across groups according to the study protocol.
Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery and will include clinical examinations and OCT imaging. The primary endpoint is anatomical macular hole closure on OCT at the prespecified primary time point. Secondary endpoints include best-corrected visual acuity (BCVA), OCT-based morphologic recovery parameters, intraoperative and postoperative complication rates, reoperation rates, and adverse event information through Year 1. The study aims to generate evidence to guide selection of surgical technique based on macular hole morphometric and clinical characteristics while maintaining patient safety.
- Conditions
- Macular Holes
- Being tested
- Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery, Autologous Platelet-Rich Plasma (PRP), Human Amniotic Membrane (hAM) Graft
- Keywords
- Full-Thickness Macular Hole, Pars Plana Vitrectomy, Internal Limiting Membrane Peeling, Inverted ILM Flap, ILM Flap, Optical Coherence Tomography, Macular Hole Closure, Best-Corrected Visual Acuity, Platelet-Rich Plasma, Amniotic Membrane Graft, Macular Hydrodissection, Surgical Technique
- Medical subject headings
- Retinal Perforations
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryProcedure or surgery
Pars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol.
Autologous Platelet-Rich Plasma (PRP)Biological
Autologous platelet-rich plasma (PRP) applied intraoperatively to the macular hole area as an adjunct to surgery, according to the study protocol.
Human Amniotic Membrane (hAM) GraftOther
Human amniotic membrane (hAM) graft placed intraoperatively for macular hole repair, according to the study protocol.
| Study group | Role | What they receive |
|---|---|---|
| PPV + PVD Induction Without ILM Peel/Flap | Active comparator | Pars plana vitrectomy (PPV) with induction of posterior vitreous detachment (PVD) performed without internal limiting membrane (ILM) peeling and without an ILM flap. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery |
| PPV + ERM peel + circular ILM peel (classic) | Active comparator | Pars plana vitrectomy (PPV) with epiretinal membrane (ERM) peeling (if present) followed by standard circular internal limiting membrane (ILM) peeling around the fovea (classic technique). Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery |
| PPV + 360° Inverted ILM Flap | Active comparator | Pars plana vitrectomy (PPV) with creation of a circumferential (360°) internal limiting membrane (ILM) flap that is inverted to cover the macular hole, according to the study protocol. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery |
| PPV + Superior Hinged ILM Flap | Active comparator | Pars plana vitrectomy (PPV) with creation of a superior hinged internal limiting membrane (ILM) flap left attached at the superior edge and inverted to cover the macular hole, according to the study protocol. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery |
| PPV + Temporal Hinged ILM Flap | Active comparator | Pars plana vitrectomy (PPV) with creation of a temporal hinged internal limiting membrane (ILM) flap, left attached at the temporal edge, and inverted to cover the macular hole, according to the study protocol. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery |
| PPV + Multiflap ILM Flap (Cabbage Leaf/Star) | Active comparator | Pars plana vitrectomy (PPV) with creation of multiple small internal limiting membrane (ILM) flaps (multiflap "cabbage leaf/star" technique) positioned to cover the macular hole, according to the study protocol. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery |
| PPV + ILM removal + inverted flap + PRP | Active comparator | Pars plana vitrectomy (PPV) with internal limiting membrane (ILM) removal and an inverted ILM flap technique. Autologous platelet-rich plasma (PRP) is applied to the macular hole area as an adjunct, according to the study protocol. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery; Biological: Autologous Platelet-Rich Plasma (PRP) |
| PPV + ILM removal + PRP | Active comparator | Pars plana vitrectomy (PPV) with standard internal limiting membrane (ILM) peeling (no ILM flap technique). Autologous platelet-rich plasma (PRP) is applied to the macular hole area as an adjunct, according to the study protocol. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery; Biological: Autologous Platelet-Rich Plasma (PRP) |
| PPV + ILM Peeling + Human Amniotic Membrane (hAM) Graft | Active comparator | Pars plana vitrectomy (PPV) with standard internal limiting membrane (ILM) peeling followed by placement of a human amniotic membrane (hAM) graft for full-thickness macular hole repair, according to the study protocol. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery; Other: Human Amniotic Membrane (hAM) Graft |
| PPV + Macular Edge Hydrodissection | Active comparator | Pars plana vitrectomy (PPV) with controlled hydrodissection (hydromobilization) of the macular hole edges using balanced salt solution to gently separate and mobilize the retinal margins before macular hole closure, according to the study protocol. Receives: Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Macular Hole Closure at 7 days
Proportion of participants with OCT-confirmed anatomical macular hole closure.
Measured: 7 day
Macular Hole Closure at 1month
Proportion of participants with OCT-confirmed anatomical macular hole closure.
Measured: 1 month
Macular Hole Closure at 1 Year
Proportion of participants with OCT-confirmed anatomical macular hole closure.
Measured: 1 year
Secondary outcomes (3)
BCVA at Day 7
Best-corrected visual acuity (BCVA) measured at Day 7 after surgery and recorded in logMAR units.
Measured: 7 days
BCVA at 1 Month
Best-corrected visual acuity (BCVA) measured at 1 month after surgery and recorded in logMAR units.
Measured: 1 month
BCVA at 1 Year
Best-corrected visual acuity (BCVA) measured at 1 year after surgery and recorded in logMAR units.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2026
- Study start25 May 2026
- Primary completion27 May 2027 (estimated)
- Study completion27 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Macular HolesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel-group randomized trial comparing ten PPV-based surgical techniques for full-thickness macular hole repair, with stratified randomization by macular hole size into five predefined MLD strata.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kazakh Eye Research Institute
- Sponsor type
- Research network
- Responsible party
- Principal investigator, Kairat Ruslanuly, Kazakh Eye Research Institute
- Investigators
- Sanzhar Sambet Sambet, MD, Principal investigator, Kazakh Eye Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07606404
- Sponsor's protocol ID
- IRB-538-2026
- Acronym
- FTMH-10
- Status last verified
- May 2026
- First submitted
- 15 May 2026
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This study does not plan to share individual participant data (IPD) publicly. De-identified aggregated results may be shared in publications and presentations.
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vitreoretinal Surgery for Full-Thickness Macular Hole: A Comparative Study of Ten Techniques
- ClinicalTrials.gov ID
- NCT07606404
- Acronym / sponsor ID
- FTMH-10 / IRB-538-2026
- Conditions
- Macular Holes
- Keywords
- Full-Thickness Macular Hole, Pars Plana Vitrectomy, Internal Limiting Membrane Peeling, Inverted ILM Flap, ILM Flap, Optical Coherence Tomography, Macular Hole Closure, Best-Corrected Visual Acuity
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Kazakh Eye Research InstituteResearch network
- Study start
- 25 May 2026 (actual)
- Primary completion
- 27 May 2027 (estimated)
- Study completion
- 27 May 2028 (estimated)
- First posted
- 26 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study compares ten modern vitreoretinal surgical techniques for full-thickness macular hole repair. Participants will be randomly assigned to one of the surgical approaches during pars plana vitrectomy, using stratified randomization based on macular hole size to ensure balanced groups. The main goal is to determine which technique provides the highest anatomical closure rate on optical coherence tomography (OCT) and the best visual outcomes. Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery to assess OCT findings, visual acuity, safety outcomes, and the need for reoperation.
Detailed description
Full-thickness macular hole is a vision-threatening condition that is commonly treated with pars plana vitrectomy (PPV) and internal limiting membrane (ILM) peeling. While standard approaches achieve high closure rates in many cases, outcomes may vary depending on macular hole size and OCT morphology, and advanced surgical strategies (e.g., different ILM flap configurations, adjunctive biologic augmentation, hydrodissection, or grafting techniques) are increasingly used in clinical practice.
This single-center, randomized, parallel-group interventional study will compare ten PPV-based surgical techniques for full-thickness macular hole repair. Eligible participants will include adults with full-thickness macular hole across a broad range of minimum linear diameter (MLD), including MLD <250 µm. After eligibility confirmation and informed consent, participants will be randomized to one of the ten procedure groups. Randomization will be stratified by macular hole size into five predefined MLD strata to ensure balanced distribution of hole sizes across all intervention groups. Postoperative care and follow-up procedures will be standardized across groups according to the study protocol.
Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery and will include clinical examinations and OCT imaging. The primary endpoint is anatomical macular hole closure on OCT at the prespecified primary time point. Secondary endpoints include best-corrected visual acuity (BCVA), OCT-based morphologic recovery parameters, intraoperative and postoperative complication rates, reoperation rates, and adverse event information through Year 1. The study aims to generate evidence to guide selection of surgical technique based on macular hole morphometric and clinical characteristics while maintaining patient safety.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 10
- Model description
- Parallel-group randomized trial comparing ten PPV-based surgical techniques for full-thickness macular hole repair, with stratified randomization by macular hole size into five predefined MLD strata.
| Arm | Type | Receives |
|---|---|---|
| PPV + PVD Induction Without ILM Peel/Flap | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryPars plana vitrectomy (PPV) with induction of posterior vitreous detachment (PVD) performed without internal limiting membrane (ILM) peeling and without an ILM flap. |
| PPV + ERM peel + circular ILM peel (classic) | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryPars plana vitrectomy (PPV) with epiretinal membrane (ERM) peeling (if present) followed by standard circular internal limiting membrane (ILM) peeling around the fovea (classic technique). |
| PPV + 360° Inverted ILM Flap | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryPars plana vitrectomy (PPV) with creation of a circumferential (360°) internal limiting membrane (ILM) flap that is inverted to cover the macular hole, according to the study protocol. |
| PPV + Superior Hinged ILM Flap | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryPars plana vitrectomy (PPV) with creation of a superior hinged internal limiting membrane (ILM) flap left attached at the superior edge and inverted to cover the macular hole, according to the study protocol. |
| PPV + Temporal Hinged ILM Flap | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryPars plana vitrectomy (PPV) with creation of a temporal hinged internal limiting membrane (ILM) flap, left attached at the temporal edge, and inverted to cover the macular hole, according to the study protocol. |
| PPV + Multiflap ILM Flap (Cabbage Leaf/Star) | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryPars plana vitrectomy (PPV) with creation of multiple small internal limiting membrane (ILM) flaps (multiflap "cabbage leaf/star" technique) positioned to cover the macular hole, according to the study protocol. |
| PPV + ILM removal + inverted flap + PRP | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery, Biological: Autologous Platelet-Rich Plasma (PRP)Pars plana vitrectomy (PPV) with internal limiting membrane (ILM) removal and an inverted ILM flap technique. Autologous platelet-rich plasma (PRP) is applied to the macular hole area as an adjunct, according to the study protocol. |
| PPV + ILM removal + PRP | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery, Biological: Autologous Platelet-Rich Plasma (PRP)Pars plana vitrectomy (PPV) with standard internal limiting membrane (ILM) peeling (no ILM flap technique). Autologous platelet-rich plasma (PRP) is applied to the macular hole area as an adjunct, according to the study protocol. |
| PPV + ILM Peeling + Human Amniotic Membrane (hAM) Graft | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery, Other: Human Amniotic Membrane (hAM) GraftPars plana vitrectomy (PPV) with standard internal limiting membrane (ILM) peeling followed by placement of a human amniotic membrane (hAM) graft for full-thickness macular hole repair, according to the study protocol. |
| PPV + Macular Edge Hydrodissection | Active comparator | Procedure: Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryPars plana vitrectomy (PPV) with controlled hydrodissection (hydromobilization) of the macular hole edges using balanced salt solution to gently separate and mobilize the retinal margins before macular hole closure, according to the study protocol. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Adults aged ≥18 years.
- Full-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV).
- Symptom duration ≤12 months.
- Clear ocular media sufficient for high-quality OCT imaging.
- No prior pars plana vitrectomy in the study eye.
Key exclusion criteria (14 listed)
- Etiology-Related / Secondary Macular Holes:
- Traumatic macular hole.
- High myopia with posterior staphyloma (axial length >28 mm and/or spherical equivalent ≤-8.0 D).
- Diabetic tractional retinal detachment (TRD) or significant tractional maculopathy.
- Retinal vascular occlusion-related macular hole.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pars Plana Vitrectomy (PPV)-Based Macular Hole SurgeryPars plana vitrectomy (PPV) for full-thickness macular hole repair performed according to the randomized assigned technique (e.g., ERM peel, ILM peeling, ILM flap configurations, or macular edge hydrodissection), as specified in the protocol. | Procedure or surgery | PPV + 360° Inverted ILM Flap, PPV + ERM peel + circular ILM peel (classic), PPV + ILM Peeling + Human Amniotic Membrane (hAM) Graft, PPV + ILM removal + PRP, PPV + ILM removal + inverted flap + PRP, PPV + Macular Edge Hydrodissection, PPV + Multiflap ILM Flap (Cabbage Leaf/Star), PPV + PVD Induction Without ILM Peel/Flap, PPV + Superior Hinged ILM Flap, PPV + Temporal Hinged ILM Flap |
| Autologous Platelet-Rich Plasma (PRP)Autologous platelet-rich plasma (PRP) applied intraoperatively to the macular hole area as an adjunct to surgery, according to the study protocol. | Biological | PPV + ILM removal + PRP, PPV + ILM removal + inverted flap + PRP |
| Human Amniotic Membrane (hAM) GraftHuman amniotic membrane (hAM) graft placed intraoperatively for macular hole repair, according to the study protocol. | Other | PPV + ILM Peeling + Human Amniotic Membrane (hAM) Graft |
Primary outcome
Macular Hole Closure at 7 days
Time frame: 7 day
Proportion of participants with OCT-confirmed anatomical macular hole closure.
Macular Hole Closure at 1month
Time frame: 1 month
Proportion of participants with OCT-confirmed anatomical macular hole closure.
Macular Hole Closure at 1 Year
Time frame: 1 year
Proportion of participants with OCT-confirmed anatomical macular hole closure.
3 secondary outcomes
BCVA at Day 7
Time frame: 7 days
BCVA at 1 Month
Time frame: 1 month
BCVA at 1 Year
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
- Individual participant dataSharing planned: No. This study does not plan to share individual participant data (IPD) publicly. De-identified aggregated results may be shared in publications and presentations.
Related trials for Macular Holes
RecruitingObservational study
Intraoperative OCT Guidance of Intraocular Surgery II
Macular Holes, Epiretinal Membrane
Recruiting
Autologous Tenon's Capsule Graft for Refractory Macular Holes
Macular Hole Surgery
Active, not recruiting
Outcomes of Macular Hole Surgery With Inverted Flap With vs Without Post op Posturing With SF6 in Macular Hole More Than 400 Micrometres
Macular Hole
Recruiting
Comparative Study of Decellularized Human Amniotic Membrane Hydrogel and Inverted Internal Limiting Membrane Flap in Idiopathic Large Macular Holes
Macular Holes
RecruitingObservational study
Surgical Procedure Efficiency Evaluation stuDy
Cataract, Vitreous Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sanzhar Sambet Sambet, MD principal investigator
Kazakh Eye Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pars Plana Vitrectomy (PPV)-Based Macular Hole Surgery, Autologous Platelet-Rich Plasma (PRP) and Human Amniotic Membrane (hAM) Graft in people with Macular Holes, run by Kazakh Eye Research Institute at 1 site in Kazakhstan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sanzhar Sambet, MD (+77758719834, sanzhrs@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Macular Hole Closure at 7 days (time frame: 7 day). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.